BioDerm Sells One Millionth Liberty3.0TM with ZERO Attributable Urinary Tract Infections (UTIs)

Share Article

In the second quarter of 2011, BioDerm sold its one millionth Liberty external continence device with ZERO attributable urinary tract infections (UTIs).

Since coming on the market in 2005, users have reported ZERO urinary tract infections attributable to Liberty.

In April 2011, the one millionth Liberty device was sold. Since coming on the market in 2005, users have reported ZERO urinary tract infections attributable to Liberty.

BioDerm General Manager, John DeBella, commented: “We are thrilled to reach the one million mark with Liberty, without a single attributable UTI. We are working hard to expand awareness of this revolutionary product within the entire healthcare community. Together, we can save the healthcare system billions and improve the standard of care for patients in every hospital in the US today.”

Urinary tract infections are a major burden on the healthcare system, costing hospitals more than $2B each year1.

The CDC estimates that more than 560,000 catheter associated urinary tract infections (CAUTI) occur each year and are the top cause of secondary blood stream infections, causing more than 13,000 deaths per year2.

According to the Association of Professionals in Infection Control (APIC), each time at CAUTI develops, it costs the hospital approximately $3,383 to treat and can add up to 4.6 days to a hospital visit1.

DeBella continued: “Many catheter-associated urinary tract infections are avoidable. Preventing them can save thousands of lives and billions of dollars. But challenging the current standard of care requires a radical new awareness of the problem and the solution.”

For more information visit us online at http://www.bioderm.us or contact Amy Coelho at (727) 507-7655 ext. 2025 or acoelho(at)bioderm(dot)us

References:
1. Calculated using the TMIT-APIC Healthcare Associated Infections Cost Calculator. Available online at: http://www.apic.org/Content/NavigationMenu/PracticeGuidance/GuidelinesStandards/Cost_Calculators.htm. Last accessed: May 18, 2011.
2. Gould, Carolyn, Catheter-associated urinary tract infection (CAUTI) toolkit, Centers for Disease Control and Prevention, Available at http://www.cdc.gov/HAI/pdfs/toolkits/CAUTItoolkit_3_10.pdf. Last accessed: May 18, 2011.
3. Data taken from the FDA’s Manufacture and User Facility Device Experience (MAUDE) database and BioDerm’s complaint handling system.

About BioDerm, Inc.
BioDerm, Inc. was founded in1990 to develop unique solutions for long-standing healthcare challenges that affect millions of people. The company’s products for urine control, and catheter securement are based on an innovative hydrocolloid technology that seals securely to skin, providing protection from moisture and bacteria.

BioDerm offers the Liberty3.0 external male continence device and the Cath GripTM catheter securement line. Liberty3.0 is the first new product for men’s urine control in 50 years. Liberty3.0 was developed to provide more freedom for men seeking a better method of bladder control and aims to make urinary output monitoring and management healthier and more comfortable.

# # #

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Amy Coelho
BioDerm Inc.
727-507-7655 2025
Email >
Visit website